MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.58 USD
-0.25 (-6.53%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $3.58 0.00 (0.00%) 6:38 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 241 - 260 ( 362 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Licenses Second Preclinical DART to J-J, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Q1 EPS; Clinical Programs On Track; Multiple Data Readouts Ahead in 2016, Reiterate OUTPERFORM and $52 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Biotechnology AACR Roundup for Covered Companies.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MGNX Highlights Broad Pipeline with Preclinical Data at AACR
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Q4:15 EPS; DART Pipeline Continues to Expand; Clinical Data Ahead, Reiterate OUTPERFORM and $52 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Enoblituzumab Checkpoint Combination - Eagerly Anticipated
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
3Q15 EPS: Clinical Programs Set Up for a Data Rich 2016, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 2This report contains brief updates on the following: DYAX, ANAC, IRWD, ECYT, FATE, XNCR, RGLS, MGNX, FCSC, SNSS, INFI, MDVN, RPTP, SRPT, XOMA, AGTC, EPZM, BLUE, PTCT, CATB, EPRS, ABUS, ICPT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Pipeline Update: Margetuximab + KEYTRUDA for Advanced Gastric Cancer
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
New Programs Announced, Encouraging Ph 1 Data for Enoblituzumab
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
How Will the Rubble Bounce, or Ideas on the Recent Sell-Off
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MGA271 Significantly Discounted at Current Levels
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D